| 2.19 -0.295 (-11.87%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.56 | 1-year : | 5.93 |
| Resists | First : | 3.91 | Second : | 5.07 |
| Pivot price | 2.59 |
|||
| Supports | First : | 2.01 | Second : | 1.68 |
| MAs | MA(5) : | 2.39 |
MA(20) : | 2.88 |
| MA(100) : | 1.87  |
MA(250) : | 4.45 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21.9 |
D(3) : | 22.6 |
| RSI | RSI(14): 41.1 |
|||
| 52-week | High : | 15 | Low : | 0.69 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BIAF ] has closed above bottom band by 14.5%. Bollinger Bands are 8.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.43 - 2.44 | 2.44 - 2.45 |
| Low: | 2.1 - 2.11 | 2.11 - 2.12 |
| Close: | 2.17 - 2.19 | 2.19 - 2.21 |
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Thu, 30 Apr 2026
Investors in bioAffinity (NASDAQ: BIAF) register 497,483 shares for resale - Stock Titan
Thu, 30 Apr 2026
bioAffinity Technologies (BIAF) wins approval for major equity plan, offerings and reverse split - Stock Titan
Tue, 28 Apr 2026
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment - ChartMill
Thu, 16 Apr 2026
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally? - TradingView
Tue, 14 Apr 2026
A 30-mm lung nodule looked cancerous; another scan showed it was not - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 5.3 (%) |
| Shares Short | 542 (K) |
| Shares Short P.Month | 221 (K) |
| EPS | -8.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.62 |
| Profit Margin | -242 % |
| Operating Margin | -197 % |
| Return on Assets (ttm) | -75.7 % |
| Return on Equity (ttm) | -301.9 % |
| Qtrly Rev. Growth | -27.8 % |
| Gross Profit (p.s.) | 0.43 |
| Sales Per Share | 1.36 |
| EBITDA (p.s.) | -2.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.26 |
| PEG Ratio | 0 |
| Price to Book value | 1.35 |
| Price to Sales | 1.59 |
| Price to Cash Flow | -1.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|